Biocon

Viatris Selling Biosimilars Unit to Biocon for $3 Billion

Viatris, the new US pharma created in the 2020 merger of Mylan and Pfizer’s Upjohn off-patent franchise, is selling its biosimilars portfolio to Biocon Biologics for up to $3.35 billion. Terms of the deal foresee Biocon paying $2 billion upfront, $1 billion in convertible preferred equity and $335 million in additional payments.

Innovation and Creativity in the Pharmaceutical Industry

The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special Recognition Awards for Operational Agility: Covid-19 Impact.

Sandoz and Biocon Collaborate on Biosimilars

Sanofi Charges Mylan With Lantus Breach

Indian Companies to Policymakers: Shape up, or we’ll ship out

The World Of Biosimilars